Table 3.
Subject demographics of the onapristone extended release (ONA-ER) pooled safety analysis (n = 88)
| Demographic | n (%) |
|---|---|
| Female | 52 (59.1) |
| Male | 36 (40.9) |
| Age, median (range) | 68.0 (36–89) |
| > 65 years | 61 (69.3) |
| Ethnicity | |
| African ancestry | 0 (0) |
| Asian | 0 (0) |
| Caucasian | 87 (98.9) |
| Unknown | 1 (0.9) |
| Tumor type | |
| Endometrial/uterine | 19 (21.5) |
| Ovarian | 12 (13.6) |
| Breast | 21 (23.9) |
| Prostate | 36 (41.0) |
| Metastases | |
| Liver | 25 (28.4) |
| Bone | 42 (47.7) |
| Treatment | |
| ONA-ER | 73 (83.0) |
| ONA-ER+ abiraterone | 15 (17.0) |